Focusing on Screening and early detection of cancer, Sansure Biotech and Singlera Genomics have reached a strategic cooperation
On June 8, Singlera Genomics (Shanghai) Ltd. (hereinafter referred to as “Singlera Genomics”) announced that it had completed a 300 million yuan B+ round of financing. This round of financing is led by Forestone Capital, followed by funds from Yinhe Yuanhui, Guojing Capital, Junci Investment, Qiandao Investment, Best, Brilliance Investment. As a strategic investor, Sansure Biotech followed the investment, and signed a strategic cooperation agreement with Singlera Genomics to focus on the field of screening and early detection of cancer. This round of financing from Singlera Genomics is mainly used to further expand the R&D pipeline of the company’s screening and early detection of cancer products, and continue to promote the registered production, commercialization and international market development of various products.
According to the latest global cancer burden data, in 2020, there were 4.57 million new cancer cases and about 3 million deaths in China. The Healthy China Action (2019-2030) proposes that by 2030, the 5-year survival rate of cancer in China will be no less than 46.6%. Screening and early detection of cancer is of great significance for the prevention and control of cancer, which can effectively reduce the burden of medical expenditure and improve the survival rate.
As a leader and promoter of methylation detection technology, Singlera Genomics has rich product pipelines. It can provide full-cycle products and services for risk assessment, early screening and diagnosis, medication guidance and recurrence monitoring of high-incidence cancers, covering pan-cancer species, lung cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, pancreatic cancer, thyroid cancer and other high-incidence cancers. Among them, ColonAiQ® is an original product in China for early screening of colorectal cancer blood polygene methylation detection. Relevant research results have been published in Gastroenterology, a top international journal in the field of gastrointestinal diseases, and have attracted wide attention. PanSeer®, a self-developed circulating tumor DNA (ctDNA) methylation pan-cancer screening technology, is the first in the world to realize the validation of the pan-cancer early screening technology in a large natural population cohort.
As a benefit provider of gene technology, Sansure Biotech has built a comprehensive product line covering different groups of people in the whole life cycle, developed more than 500 products with excellent performance, and further expanded to the field of screening and early detection of cancer, and personalized medicine for cancer. Through independent research and development or the introduction of methylation, liquid biopsy and multi-omics early screening and diagnosis products, the company develops molecular diagnostic solutions for screening and early detection of cancer, which are used for full-cycle products and services such as risk assessment, early screening and diagnosis, medication guidance and recurrence detection for high-incidence cancers. Among them, the preclinical experimental study of the early screening reagent for liver cancer based on DNA methylation detection independently developed by Sansure Biotech has been completed.
At present, the field of screening and early detection of cancer is entering a period of rapid growth. The strategic investment in Singlera Genomics by Sansure Biotech will give full play to the advantages of both sides, and achieve mutual benefit in product development, domestic and international market sales and livelihood projects through in-depth strategic cooperation in the field of screening and early detection of cancer.
In the future, the two sides plan to establish a joint venture to carry out extensive cooperation in livelihood projects in accordance with relevant national policies and in combination with the advantages of both sides, so as to contribute to improving the health level of the whole people. The two parties will also carry out extensive cooperation in ctDNA extraction, methylation processing automation equipment, cancer species, cancer application segments, and international market development.
